The Life Sciences team represented Rubius Therapeutics (NASDAQ: RUBY) in the upsized underwritten public offering of 6,896,552 shares of its common stock at a public offering price of $29.00 per share. The gross proceeds to Rubius from the offering were approximately $200 million, before deducting the underwriting discounts and commissions and other offering expenses. Rubius has granted the underwriters a 30-day option to purchase up to an additional 1,034,482 shares of its common stock.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
The Goodwin team was led by Stuart Cable, Arthur McGivern, Sarah Ashfaq, Ki Hoon Kim, Kaitlin Carragher and included Julie Tibbets, Janet Andolina, Andrew Wilson, Claire Oxford with invaluable assistance from Ettore Santucci, James Matarese and Pamela Finan.For additional details on the offering, please read the press release.